Skip to main content
TipRanks
Go Ultimate75% OFF

Zentek (ZAY0) AI Stock Analysis

1 Followers
DE:ZAY0

Zentek

(Frankfurt:ZAY0)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low leverageVery modest leverage gives Zentek greater financial flexibility than a heavily indebted business. Lower debt obligations can reduce refinancing pressure and leave more capacity to fund commercialization, research, or partnerships while absorbing operating volatility.
Negative Factors
Severe revenue contractionThe sharp and persistent revenue contraction indicates that Zentek has not yet established a stable commercial growth engine. Weak top-line performance can limit operating leverage, reduce funding available for development, and make future results highly dependent on successful commercialization milestones.

Zentek (ZAY0) vs. iShares MSCI Germany ETF (EWG)

-60%-40%-20%0%20%40%60%DE:ZAY0-46.02%EWG+3.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 62.30M
Dividend Yield
―
Average Volume (3M)
2,595
Price to Earnings (P/E)
8.0
Beta (1Y)
0.50
Revenue Growth
-89.01%
EPS Growth
―
Country
Germany
Employees
24
Sector
Basic Materials
Sector Strength
61
Industry
Medical - Instruments & Supplies

Zentek Business Overview & Revenue Model

Company Description

Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating u...

Zentek Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

DE:ZAY0 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:MDPTSE:MDP63NeutralCAD 179.44M-99.08-2.49%―2.62%-337.50%
Sector *61Neutral$10.43B7.12-0.05%2.87%2.86%-36.73%
TSE:ARCHTSE:ARCH43NeutralCAD 59.78M-20.7074.79%――-15.53%
TSE:BUXTSE:BUX42NeutralCAD 44.72M-31.11-250.77%―-82.05%23.73%
TSE:SONATSE:SONA37UnderperformCAD 31.93M-12.15448.05%――24.65%

* Basic Materials Sector Average

Performance Comparison

-50%0%50%100%DE:ZAY0TSE:ARCHTSE:BUXTSE:MDPTSE:SONADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:ZAY0 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:ZAY0Zentek Ltd.0.33-0.30-47.30%
TSE:ARCHArch Biopartners0.88-0.17-16.19%
TSE:BUXBioMark Diagnostics0.420.0720.00%
TSE:MDPMedexus Pharmaceuticals5.713.00110.70%
TSE:SONASona Nanotech, Inc0.26-0.24-48.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.